研究结果显示,对于PD-L1表达阳性的晚期NSCLC患者,靶免联合方案具有一定的抗肿瘤作用,且安全性可控,尤其在PD-L1高表达人群中获益更为显著。而在后线治疗方面,基于ORIENT-31研究[10],已有一项靶免联合治疗方案获得了《2024 CSCO非小细胞肺癌诊疗指南》[11]中治疗晚期EGFR突变非小细胞肺癌的Ⅲ级推荐。研究结果显示,信...
7. Jie Wang, Zhijie Wang, Lin Wu, et al. Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC ...
We’ve heard it before, but maybe - just maybe - we’re at the brink of a new frontier for cancer care.ESMO 2024 has just wrapped up in Barcelona and the take-home message is unlike any other oncology congress in recent memory. There’s a palpable shift in energy and expectation, wit...
[5]https://www.prnewswire.com/news-releases/biosyngens-first-in-class-car-t-asset-targeting-solid-tumors-has-entered-pivotal-phase-ii-trial-phase-i-trial-data-debut-at-esmo-2024-annual-congress-302251709.html [6]...
会议期间,大会公布了众多可能对临床实践产生重大影响的研究数据,并促进多学科的深入讨论,以期改善患者的治疗方案选择。 作为成功“出海”的代表性中国原研药,特瑞普利单抗多项研究在2024年ESMO年会中亮相,得到了多方关注。 在肺癌领域,一项索凡替尼联合特瑞普利单抗、
作为成功“出海”的代表性中国原研药,特瑞普利单抗多项研究在2024年ESMO年会中亮相,得到了多方关注。在肺癌领域,一项索凡替尼联合特瑞普利单抗、培美曲塞(A)和铂类(P)化疗用于晚期非鳞状非小细胞肺癌(nsq-NSCLC)患者的单中心、Ⅱ期研究的更新结果荣登壁报展示环节(#1345P)[1]。研究结果提示四药联合方案不受驱动...
Andrew Joseph — STAT This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. There are no more editions this year, but you can keep up with biopharma news by signing up forSTAT’s The Re...
作为成功“出海”的代表性中国原研药,特瑞普利单抗多项研究在2024年ESMO年会中亮相,得到了多方关注。在肺癌领域,一项索凡替尼联合特瑞普利单抗、培美曲塞(A)和铂类(P)化疗用于晚期非鳞状非小细胞肺癌(nsq-NSCLC)患者的单中心、Ⅱ期研究的更新结果荣登壁报展示环节(#1345P)[1]。研究结果提示四药联合方案不受驱动...
ASCO Annual Meetinggastrointestinal malignancyESMO Congresscolorectal canceresophagogastric cancercirculating tumor DNA (ctDNA)clinical trialsBACKGROUND. Gastrointestinal (GI) malignancies remain the culprit behind a substantial portion of cancer-related mortality worldwide, and outcomes for patients with ...
2024年欧洲肿瘤内科学会乳腺癌年会(2024 ESMO BREAST CANCER Annual Congress)将于5月15日至17日(CEST)在德国柏林会展中心举行。本次大会涵盖转化研究、新药物开发、分子与功能性诊断、生物标志物的应用、前沿科技的研究,以及患者护理等...